ISOLATED ANTI-CD30 ANTIBODY (VERSIONS); HOST CELL, METHOD OF OBTAINING CHIMERIC OR HUMANISED VERSION OF ANTI-CD30 ANTIBODIES (VERSIONS), METHOD OF INHIBITING GROWTH OF CELLS CD30+ AND METHOD OF INHIBITING GROWTH OF TUMOUR CELLS EXPRESSING CD30 Russian patent published in 2013 - IPC C07K16/30 C12N5/10 A61K39/395 A61P35/00 

FIELD: medicine, pharmaceutics.

SUBSTANCE: claimed invention relates to field of immunology. Claimed are versions of isolated anti-CD30 antibody, in fact free of fucosyl residues. Claimed antibody is characterised by the fact that it contains in one version 3 CDR from heavy chain and three CDR from light chain, in the other version it is characterised by presence of variable region of heavy chain and variable region of light chain. Described is host cell, producing said antibody, in fact free of fucosyltransferase, described is method of inhibiting growth of cells CD30+ and method of inhibiting growth of tumour cells expressing CD30 with application of antibody. Described are versions of antibody application for obtaining chimeric or humanised version of antibody.

EFFECT: antibodies by claimed invention demonstrate increased ADCC cell cytotoxicity with respect to lines of cells of Hodgkin human lymphoma: L428, L540, L1236 and line of T-cell human lymphoma: KARPAS, expressing CD30, which are not lysed by fucolysed form of antibodies.

24 cl, 15 dwg, 4 tbl, 6 ex